Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

cell therapies

This page shows the latest cell therapies news and features for those working in and with pharma, biotech and healthcare.

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

industry. Recent examples of this include rapid pricing deals on the two CAR-T therapies, Novartis’ Kymriah and Gilead’s Yescarta. ... This includes cell and gene therapies such as Novartis’ late-stage candidate Zolgensma, which the company has

Latest news

  • NCI head Sharpless named as interim FDA chief NCI head Sharpless named as interim FDA chief

    therapies such as cell and gene therapies, whilst encouraging greater competition to products at the other end of their lifespan from generics and biosimilars.

  • Oxford Biomedica taps Microsoft to progress gene therapy delivery tech Oxford Biomedica taps Microsoft to progress gene therapy delivery tech

    These new technologies will help advance the next generation of cell and gene delivery approaches, the companies claim. ... Our goal is to enable faster, cheaper and more reliable manufacture of high quality next-generation cell and gene therapies to

  • Novartis and Syncona back new Swiss biotech Anaveon Novartis and Syncona back new Swiss biotech Anaveon

    including combination with cell therapies, vaccines, checkpoint inhibitors and radiotherapy. ... Anaveon has a strong strategic fit across Syncona’s cell therapy portfolio and we are excited by the potential to develop a best-in-class product in the

  • Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

    Mogrify will undoubtedly present a new kind of challenge for Disley however, as the company looks to lead a transformative change in the development of cell therapies. ... The platform can also be applied to other treatment areas, including cardiac

  • AbbVie enters BCMA race with Teneobio deal AbbVie enters BCMA race with Teneobio deal

    Teneobio to co-develop and commercialise its B-cell maturation antigen (BCMA) targeting candidate. ... of CAR-Ts, they could emerge as the new standard of care, not having the complicated and expensive manufacturing process with the cell therapies, and

More from news
Approximately 2 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    For cell therapies, the issue is that manufacture is geared to one person, so one batch equals one dose. ... And even for allogeneic cell therapies and gene therapies, raw materials and analytical testing costs will also need to be reduced” Davies said.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... and that therapies based on the approach must be

  • Launch trends 2019 Launch trends 2019

    Companies also need to adapt to new commercialisation challenges for novel therapeutic modalities like gene and cell therapies. ... How should companies plan and invest in this? New cell therapies face challenges with manufacturing costs, storage and

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... oral therapies such as Tyk inhibitors from Bristol-Myers Squibb

  • China’s clinical trial shake-up China’s clinical trial shake-up

    Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

More from intelligence
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest appointments

  • Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

    Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Abeona Therapeutics appoints new additions to board of directors Abeona Therapeutics appoints new additions to board of directors

    Stefano Buono and Richard Van Duyne join the biopharma. Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the ... He said: “Abeona’s ambitious

  • Turnstone Biologics bolsters leadership team Turnstone Biologics bolsters leadership team

    Prior to his new role, he was chief business officer at SQZ Biotech, a clinical-stage group focusing on developing cell therapies.

  • Avita Medical appoints CEO Avita Medical appoints CEO

    chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... Prior to Novartis Perry was global head of R&D for the bioscience division at Baxter Healthcare, vice president of

More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Quick links

Infographics

Multimedia